This study was done to quality assure the Hawkeye
SPECT/CT at the St.Olav’s hospital and create a clinical method for
doing individual dosimetry with 177Lu-octreotate
in targeted radionuclide therapy for neuroendocrine tumors. Various quality control
parameters were performed on Infinia Hawkeye SPECT/CT. A calibration dose of
160%±2% MBq was ordered and first
calibrated for all the dose calibrators. The uniformity test was obtained using
a 40 MBq Tc-99m point source positioned 2.5 m away from the two detectors. A 200 MBq Tc-99m was diluted in 70 ml of
water, dispersed in six syringes for the registration test. A Lu-177
pointsource
was placed in front of the detectors, one at a time, to check
the energy peaks. The Jaczczak phantom with a hollow sphere set (volumes: 0.5, 1, 2, 4, 8, and 16)
ml with an additional 60 ml sphere was used for the 3D sensitivity and recovery
with Lu-177. Total activity of 945.3MBq was added to 160 ml of water yielding an activity concentration of 5.908MBq/ml
in the spheres. The phantom was then scanned at various time intervals. A
cylindrical phantom with a volume of 6283 ml was also used to obtain the
cross-calibration measurement (cps/MBq). Total activity of 995.6
MBq was added and the phantom was scanned at days 0, 6, 13 and 23. The
dose calibration factor was changed from 762 to 760 to achieve correctdoses. The 2D mean sensitivity factor was 5.56
cps/MBq. Uniformities for
References
[1]
Mattsson, S. and Söderberg, M. (2011) Radiation Dose Management in CT, SPECT/CT and PET/CT Techniques. Radiation Protection Dosimetry, 147, 13-21. https://doi.org/10.1093/rpd/ncr261
[2]
Mhiri, A., Slim, I., Ghezaiel, M., Meddeb, I., El Bez, I., Yeddes, I., et al. (2012) L’apport de l’imagerie hybride TEMP/TDM dans la prise en charge du cancer différencié de la thyroïde. Médecine Nucléaire. Imagerie Fonctionnelle et Métabolique, 36, 554-560. https://doi.org/10.1016/j.mednuc.2012.08.008
[3]
Larkin, A.M., Serulle, Y., Wagner, S., Noz, M.E. and Friedman, K. (2011) Quantifying the Increase in Radiation Exposure Associated with SPECT/CT Compared to SPECT Alone for Routine Nuclear Medicine Examinations. International Journal of Molecular Imaging, 2011, Article ID: 897202. https://doi.org/10.1155/2011/897202
[4]
Wall, B.F. and Hart, D. (1997) Revised Radiation Doses for Typical X-Ray Examinations: Reports on Recent Review of Doses to Patients from Medical X-ray Examinations in the UK by NRPB. The British Journal of Radiology, 70, 437-439. https://doi.org/10.1259/bjr.70.833.9227222
[5]
International Commission on Radiological Protection (ICRP) (1991) 1990 Recommendations of the International Commission on Radiological Protection. ICRP publication No. 60, Pergamon Press, New York.
[6]
International Commission on Radiological Protection (ICRP) (2007) 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication No. 103. Annals of the ICRP, 37, 1-332.
[7]
Snyder, W.S., Ford, M.R., Warner, G.G. and Watson, S.B. (1975) “S” Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs (Part 1). MIRD Pamphlet 11. The Society of Nuclear Medicine, New York.
[8]
Sandstrom, M., Garske, U., Granberg, D., Sundin, A. and Lundqvist, H. (2010) Individualized Dosimetry in Patients Undergoing Therapy with 177Lu-DOTA-D-Phe1-Tyr3-Octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 37, 212-225. https://doi.org/10.1007/s00259-009-1216-8
[9]
Garkavij, M., Nickel, M., Sjogreen-Gleisner, K., Ljungberg, M., Ohlsson, T., Wingardh, K., et al. (2010) 177Lu-[DOTA0, Tyr3] Octreotate Therapy in Patients with Disseminated Neuroendocrine Tumors: Analysis of Dosimetry with Impact on Future Therapeutic Strategy. Cancer, 116, 1084-1092. https://doi.org/10.1002/cncr.24796
[10]
Sward, C., Bernhardt, P., Ahlman, H., Wangberg, B., Forssell-Aronsson, E., Larsson, M., et al. (2010) [177Lu-DOTA0-Tyr3]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney. World Journal of Surgery, 34, 1368-1372. https://doi.org/10.1007/s00268-009-0387-6
[11]
Fjalling, M., Andersson, P., Forssell-Aronsson, E., Gretarsdottir, J., Johansson, V., Tisell, L.E., et al. (1996) Systemic Radionuclide Therapy Using Indium-111-DTPA-DT Phe1-Octreotide in Midgut Carcinoid Syndrome. Journal of Nuclear Medicine, 37, 1519-1521.
[12]
Gabriel, M., Andergassen, U., Putzer, D., Kroiss, A., Waitz, D., Von Guggenberg, E., et al. (2010) Individualized Peptide-Related-Radionuclide-Therapy Concept Using Different Radiolabelled Somatostatin Analogs in Advanced Cancer Patients. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 54, 92-99.
[13]
Kwekkeboom, D.J., de Herder, W.W., van Eijck, C.H., Kam, B.L., van Essen, M., Teunissen, J.J., et al. (2010) Peptide Receptor Radionuclide Therapy in Patients with Gastro-enteropancreatic Neuroendocrine Tumors. Seminars in Nuclear Medicine, 40, 78-88. https://doi.org/10.1053/j.semnuclmed.2009.10.004
[14]
Kwekkeboom, D.J., Kam, B.L., van Essen, M., Teunissen, J.J., van Eijck, C.H., Valkema, R., et al. (2010) Somatostatin-Receptor-Based Imaging and Therapy of Gastroentero-pancreatic Neuroendocrine Tumors. Endocrine-Related Cancer, 17, R53-R73. https://doi.org/10.1677/ERC-09-0078
[15]
Seregni, E., Maccauro, M., Coliva, A., Castellani, M.R., Bajetta, E., Aliberti, G., et al. (2010) Treatment with Tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of Neuroendocrine Tumors Refractory to Conventional Therapy: Preliminary Results. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 54, 84-91.
[16]
van Essen, M., Krenning, E.P., Kam, B.L., de Herder, W.W., Feelders, R.A. and Kwekke-boom, D.J. (2010) Salvage Therapy with (177)Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine, 51, 383-390. https://doi.org/10.2967/jnumed.109.068957
[17]
Esser, J.P., Krenning, E.P., Teunissen, J.J., Kooij, P.P., van Gameren, A.L., Bakker, W.H., et al. (2006) Comparison of [177Lu-DOTA0,Tyr3]Octreotate and [177Lu-DOTA0,Tyr3]Octreotide: Which Peptide Is Preferable for PRRT? European Journal of Nuclear Medicine and Molecular Imaging, 33, 1346-1351. https://doi.org/10.1007/s00259-006-0172-9
[18]
Tolmachev, V., Bernhardt, P., Forssell-Aronsson, E. and Lundqvist, H. (2000) 114mIn, a Candidate for Radionuclide Therapy: Low-Energy Cyclotron Production and Labeling of DTPA-D-Phe-Octreotide. Nuclear Medicine and Biology, 27, 183-188. https://doi.org/10.1016/S0969-8051(99)00096-7
[19]
Rossin, R., Pan, D., Qi, K., Turner, J.L., Sun, X., Wooley, K.L., et al. (2005) 64Cu-Labeled Folate-Conjugated Shell Cross-Linked Nanoparticles for Tumor Imaging and Radiotherapy: Synthesis, Radiolabeling, and Biologic Evaluation. Journal of Nuclear Medicine, 46, 1210-1218.
[20]
Smith, S.V. (2004) Molecular Imaging with Copper-64. Journal of Inorganic Biochemistry, 98, 1874-1901. https://doi.org/10.1016/j.jinorgbio.2004.06.009
[21]
Mansi, L. and Virgolini, I. (2011) Diagnosis and Therapy Are Walking Together on Radiopeptides’ Avenue. European Journal of Nuclear Medicine and Molecular Imaging, 38, 605-612. https://doi.org/10.1007/s00259-011-1762-8
